
Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar
pharmafile | April 8, 2016 | News story | Medical Communications, Research and Development | Sandoz, binocrit, biosimilar, eu approval
Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route of administration in Binocrit’s (epoetin alfa) nephrology indication.
This approval is based on data from the SENSE clinical study which evaluated the safety and immunogenicity of HX575 epoetin alfa in the treatment of anaemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
Carol Lynch, global head of biopharmaceuticals at Sandoz, says: “By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients.”
Sean Murray
Related Content

Sandoz launches two new bone disease biosimilars in Europe
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …

Sandoz signs renewable energy deal to supply 90% of European operations
Sandoz has entered into a ten-year virtual Power Purchase Agreement with Elawan Energy for the …

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar
Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation …





